40. Cell-free DNA fragmentation profiling as a method for tumor fraction assessment and treatment monitoring in NSCLC

Available cfDNA assays have shown potential for tracking tumor progression during therapy in patients with metastatic cancers. However, these approaches typically require deep-targeted sequencing to detect cancer-specific mutations at low mutant allele frequency (MAF) levels in the circulating blood. We developed DELFI-Tumor Fraction (DELFI-TF), a mutation-independent approach that utilizes low-coverage whole genome sequencing (WGS) to predict plasma tumor fractions based on genome-wide fragmentation-related features.

Source: Cancer Genetics and Cytogenetics - November 1, 2023 Category: Genetics & Stem Cells Authors: Zachary Skidmore, Bahar Alipanahi, Lorenzo Rinaldi, Nicholas Dracopoli, Alessandro Leal Source Type: research